1-4 of 4
Errin Samuëlsz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study

Daniel H. Ahn, Afsaneh Barzi, Maya Ridinger, Errin Samuëlsz, Ramanand A. Subramanian, Peter J.P. Croucher, Tod Smeal, Fairooz F. Kabbinavar, Heinz-Josef Lenz
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2039–2047.
https://doi.org/10.1158/1078-0432.CCR-23-3053
Published: 15 May 2024
View article titled, Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of <em>KRAS</em>-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study
Open the PDF for Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of <em>KRAS</em>-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study in another window
Includes: Supplementary data
Journal Articles

A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Amer M. Zeidan, Maya Ridinger, Tara L. Lin, Pamela S. Becker, Gary J. Schiller, Prapti A. Patel, Alexander I. Spira, Michaela L. Tsai, Errin Samuëlsz, Sandra L. Silberman, Mark Erlander, Eunice S. Wang
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (23): 6132–6140.
https://doi.org/10.1158/1078-0432.CCR-20-2586
Published: 01 December 2020
View article titled, A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Open the PDF for A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Abstract A43: Plasma-derived circulating tumor DNA (ctDNA) as a surrogate biomarker for treatment response with the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with LDAC or decitabine in acute myeloid leukemia (AML)

Errin Samuelsz, Maya Ridinger, Mark Erlander, Latifa Hassaine, Marion Luebbermann, Brittany Ross
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11_Supplement): A43.
https://doi.org/10.1158/1557-3265.LiqBiop20-A43
Published: 01 June 2020
View article titled, Abstract A43: Plasma-derived circulating tumor DNA (ctDNA) as a surrogate biomarker for treatment response with the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with LDAC or decitabine in acute myeloid leukemia (AML)
Journal Articles

Abstract 30: Quantitative monitoring of EGFR mutations in urinary circulating tumor DNA enables non-invasive pharmacodynamic assessment of anti-EGFR drug response

Hatim Husain, Karena Kosco, Saege Hancock, Errin Samuelsz, Shiloh Guerrero, Brian Woodward, Cecile Rose Vibat, Vlada Melnikova, Mark Erlander, Scott Lippman, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (1_Supplement): 30.
https://doi.org/10.1158/1557-3265.PMSCLINGEN15-30
Published: 03 January 2016
View article titled, Abstract 30: Quantitative monitoring of EGFR mutations in urinary circulating tumor DNA enables non-invasive pharmacodynamic assessment of anti-EGFR drug response